Three key developments for $HAE as Haemonetics expands its plasma and medical technology businesses. • Plasma expansion: CSL Plasma plans to deploy Haemonetics’ NexSys PCS systems with Persona PLUS technology across all its existing U.S. collection centers by the end of 2027. • Clinical results: A study of 1,623 patients using VASCADE MVP XL reported a 92.5% same-day discharge rate and just 1.2% vascular complications. • Earnings growth: Fiscal Q1 revenue rose 5.5% YoY to $339M, beating expectations. Haemonetics also raised its full-year revenue and earnings guidance. A broader plasma partnership, encouraging clinical data, and an improved financial outlook put $HAE in focus. $HAE is available to trade on StableStock: → #HAE# #MedTech# #Healthcare# Not investment advice. For informational purposes only.